Sensory Cloud has announced the publication of an article in ERJ Open Research presenting data from a study of its SC001 intranasal alkaline hypertonic divalent salt in patients with refractory chronic cough (RCC). The company says it will now advance an orally inhaled formulation, SC0023 alkaline hypertonic divalent salt, into a Phase 2a trial.
The study, which was conducted at Imperial College London, evaluated SC001 at pH 8 and at pH 9 in 12 patients with RCC. After one week of cough monitoring, patients received one week of a saline nasal spray control followed by one week of SC001 as a nasal spray. Cough frequency was reduced by up to 35% for SC001 pH 9 on Day 3 as measured by a digital cough monitor, the authors report.
Sensory Cloud CSO David A. Edwards commented, “Dehydration of human upper airways worsens respiratory illnesses. The clinical trial results suggesting that cough frequency in RCC is reduced rapidly and across the entire range of cough rates with an endogenous rehydrating aerosol are encouraging for the potential of safely treating RCC, and possibly other chronic respiratory diseases provoked by dysfunction of the airway lining.”
Read the Sensory Cloud press release.
